- TECNIS PureSee IOL will be available in the U.S. later this year.
- Cataract surgery is one of the safest and most common procedures worldwide.
- 94 million people over 50 have vision impairment correctable by lens replacement.
- TECNIS PureSee IOL is the first FDA-approved EDOF IOL without contrast sensitivity warnings.
FDA Approval
Johnson & Johnson's TECNIS PureSee IOL has received FDA approval for use in cataract surgery. This extended depth of focus intraocular lens aims to improve vision clarity for patients.
Patient Benefits
TECNIS PureSee IOL addresses cataract-related vision loss and presbyopia, reducing reliance on glasses. It maintains contrast sensitivity comparable to aspheric monofocal IOLs, with 97% of patients reporting no very bothersome visual disturbances.
Market Impact
Cataract surgery is a common procedure worldwide, offering vision enhancement opportunities. An estimated 94 million people over 50 have vision impairment that could be corrected through lens replacement surgery.
Product Features
TECNIS PureSee IOL is the first FDA-approved EDOF IOL without warnings on contrast sensitivity loss. It combines advanced optics with proprietary material to provide extended depth of focus, enabling excellent distance and intermediate vision.
